These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 39225258)

  • 1. Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.
    Cho MS; Kang DY; Ahn JM; Yun SC; Oh YS; Lee CH; Choi EK; Lee JH; Kwon CH; Park GM; Choi HO; Park KH; Park KM; Hwang J; Yoo KD; Cho YR; Kim JH; Hwang KW; Jin ES; Kwon O; Kim KH; Park SJ; Park DW; Nam GB;
    N Engl J Med; 2024 Sep; ():. PubMed ID: 39225258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Edoxaban-based long-term antithrombotic therapy in patients with atrial fibrillation and stable coronary disease: Rationale and design of the randomized EPIC-CAD trial.
    Cho MS; Kang DY; Oh YS; Lee CH; Choi EK; Lee JH; Kwon CH; Park GM; Park HW; Park KH; Park KM; Hwang J; Yoo KD; Cho YR; Kim YR; Hwang KW; Jin ES; Kim PJ; Kim KH; Park DW; Nam GB
    Am Heart J; 2022 May; 247():123-131. PubMed ID: 35149036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease.
    Fukamachi D; Okumura Y; Matsumoto N; Tachibana E; Oiwa K; Ichikawa M; Haruta H; Nomoto K; Arima K; Hirayama A
    J Interv Cardiol; 2022; 2022():5905022. PubMed ID: 36619818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
    Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
    N Engl J Med; 2019 Sep; 381(12):1103-1113. PubMed ID: 31475793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study).
    Lip GYH; Merino JL; Dan GA; Themistoclakis S; Ellenbogen KA; De Caterina R; Goudev A; Jin J; Melino M; Winters SM; Goette A
    Am J Cardiol; 2018 Jan; 121(2):193-198. PubMed ID: 29169605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of rivaroxaban-based dual antithrombotic and antiplatelet therapies for symptomatic patients with lower-extremity peripheral artery disease post-revascularization: a retrospective cohort study.
    Ji Y; Wang B; Wu G; Zhang Y; Wang Q; Zhou M
    Ther Adv Chronic Dis; 2023; 14():20406223231213262. PubMed ID: 38085917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.
    Cannon CP; Gropper S; Bhatt DL; Ellis SG; Kimura T; Lip GY; Steg PG; Ten Berg JM; Manassie J; Kreuzer J; Blatchford J; Massaro JM; Brueckmann M; Ferreiros Ripoll E; Oldgren J; Hohnloser SH;
    Clin Cardiol; 2016 Oct; 39(10):555-564. PubMed ID: 27565018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
    Van Mieghem NM; Unverdorben M; Hengstenberg C; Möllmann H; Mehran R; López-Otero D; Nombela-Franco L; Moreno R; Nordbeck P; Thiele H; Lang I; Zamorano JL; Shawl F; Yamamoto M; Watanabe Y; Hayashida K; Hambrecht R; Meincke F; Vranckx P; Jin J; Boersma E; Rodés-Cabau J; Ohlmann P; Capranzano P; Kim HS; Pilgrim T; Anderson R; Baber U; Duggal A; Laeis P; Lanz H; Chen C; Valgimigli M; Veltkamp R; Saito S; Dangas GD;
    N Engl J Med; 2021 Dec; 385(23):2150-2160. PubMed ID: 34449183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial.
    Vranckx P; Lewalter T; Valgimigli M; Tijssen JG; Reimitz PE; Eckardt L; Lanz HJ; Zierhut W; Smolnik R; Goette A
    Am Heart J; 2018 Feb; 196():105-112. PubMed ID: 29421002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial.
    Kuroda M; Tamiya E; Nose T; Ogimoto A; Taura J; Imamura Y; Fukuzawa M; Hayashi T; Akao M; Yamashita T; Lip GYH; Okumura K
    JAMA Cardiol; 2022 Jun; 7(6):583-590. PubMed ID: 35416910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    Cannon CP; Bhatt DL; Oldgren J; Lip GYH; Ellis SG; Kimura T; Maeng M; Merkely B; Zeymer U; Gropper S; Nordaby M; Kleine E; Harper R; Manassie J; Januzzi JL; Ten Berg JM; Steg PG; Hohnloser SH;
    N Engl J Med; 2017 Oct; 377(16):1513-1524. PubMed ID: 28844193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.
    Naito R; Miyauchi K; Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H;
    JAMA Cardiol; 2022 Aug; 7(8):787-794. PubMed ID: 35704345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
    Vranckx P; Valgimigli M; Eckardt L; Tijssen J; Lewalter T; Gargiulo G; Batushkin V; Campo G; Lysak Z; Vakaliuk I; Milewski K; Laeis P; Reimitz PE; Smolnik R; Zierhut W; Goette A
    Lancet; 2019 Oct; 394(10206):1335-1343. PubMed ID: 31492505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
    Lamberts M; Gislason GH; Lip GY; Lassen JF; Olesen JB; Mikkelsen AP; Sørensen R; Køber L; Torp-Pedersen C; Hansen ML
    Circulation; 2014 Apr; 129(15):1577-85. PubMed ID: 24470482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation.
    Matsumura-Nakano Y; Shizuta S; Komasa A; Morimoto T; Masuda H; Shiomi H; Goto K; Nakai K; Ogawa H; Kobori A; Kono Y; Kaitani K; Suwa S; Aoyama T; Takahashi M; Sasaki Y; Onishi Y; Mano T; Matsuda M; Motooka M; Tomita H; Inoko M; Wakeyama T; Hagiwara N; Tanabe K; Akao M; Miyauchi K; Yajima J; Hanaoka K; Morino Y; Ando K; Furukawa Y; Nakagawa Y; Nakao K; Kozuma K; Kadota K; Kimura K; Kawai K; Ueno T; Okumura K; Kimura T;
    Circulation; 2019 Jan; 139(5):604-616. PubMed ID: 30586700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
    Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
    Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Edoxaban versus warfarin in patients with atrial fibrillation.
    Giugliano RP; Ruff CT; Braunwald E; Murphy SA; Wiviott SD; Halperin JL; Waldo AL; Ezekowitz MD; Weitz JI; Špinar J; Ruzyllo W; Ruda M; Koretsune Y; Betcher J; Shi M; Grip LT; Patel SP; Patel I; Hanyok JJ; Mercuri M; Antman EM;
    N Engl J Med; 2013 Nov; 369(22):2093-104. PubMed ID: 24251359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events.
    Lemesle G; Ducrocq G; Elbez Y; Van Belle E; Goto S; Cannon CP; Bauters C; Bhatt DL; Steg PG;
    Clin Cardiol; 2017 Oct; 40(10):932-939. PubMed ID: 28692742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis.
    Akao M; Yasuda S; Kaikita K; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H
    Am Heart J; 2021 Jun; 236():59-68. PubMed ID: 33657403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.